ArticleInternational journal of STD & AIDS2021
HIV-associated tuberculosis.
Article in International journal of STD & AIDS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Determinants of HIV related mortality in African children on antiretroviral therapy: clinical and immunological insights from a systematic review and meta-analysis.AIDS research and therapy · 2025Pooled it
- Pooled it
- Health care providers acceptance of default prescribing of TB preventive treatment for people living with HIV in Malawi: a qualitative study.BMC health services research · 2024Trial
- The Impact of HIV Viral Suppression and Immune Status on Rifampicin-Resistant Tuberculosis Outcomes: A Systematic Review and Meta-Analysis Protocol.Tropical medicine and infectious disease · 2026Review
- The many faces of extrapulmonary tuberculosis: A case series.Journal of family medicine and primary care · 2026Article
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Using interpretable decision trees to explore TB-HIV integration under data constraints: a proof-of-concept analysis.Frontiers in tuberculosis · 2026Article
- Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and DisputedPathogens (Basel, Switzerland) · 2025Review
- A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum.Journal of clinical microbiology · 2025Article
- Understanding Cholesterol-Mycolic Acid-Phosphatidylcholine Interactions: Advancing Electrochemical Detection of Tuberculosis.ACS omega · 2025Article
- Extrapulmonary tuberculosis in The Netherlands, an epidemiologic overview, 1993-2022.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Determinants of Non-Adherence to Anti-Tuberculosis Treatment in a Public Primary Healthcare Clinic in South Africa: Improving the Quality of Long-Term Care.International journal of environmental research and public health · 2025Article
- Outcomes of Treating Tuberculosis Patients with Drug-Resistant Tuberculosis, Human Immunodeficiency Virus, and Nutritional Status: The Combined Impact of Triple Challenges in Rural Eastern Cape.International journal of environmental research and public health · 2025Article
- Schistosomiasis Interventions in Africa: Assessment and Systematic Review.Journal of parasitology research · 2025Review
- Assessment of comorbidities, risk factors, and post tuberculosis lung disease in National Tuberculosis Guidelines: A scoping review.PLOS global public health · 2025Article
- Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Advanced pulmonary tuberculosis in Alameda County: Ten-year incidence and risk factors.Journal of clinical tuberculosis and other mycobacterial diseases · 2024Article
- Physical and psychological impact of HIV/AIDS toward youths in Southwest Ethiopia: a phenomenological study.BMC public health · 2024Article
- A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management.Cureus · 2024Review
- Decreased IL-1 β Secretion as a Potential Predictor of Tuberculosis Recurrence in Individuals Diagnosed with HIV.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living with HIV. HIV-associated TB disproportionally affects African countries, particularly vulnerable groups at risk for both TB and HIV. Currently available TB diagnostics perform poorly in people living with HIV; however, new diagnostics such as Xpert Ultra and lateral flow urine lipoarabinomannan assays can greatly facilitate diagnosis of TB in people living with HIV. TB preventive treatment has been underutilized despite its proven benefits independent of antiretroviral therapy (ART). Shorter regimens using rifapentine can support increased availability and scale-up. Mortality is high in people with HIV-associated TB, and timely initiation of ART is critical. Programs should provide decentralized and integrated TB and HIV care in settings with high burden of both diseases to improve access to services that diagnose TB and HIV as early as possible. The new prevention and diagnosis tools recently recommended by WHO offer an immense opportunity to advance our fight against HIV-associated TB. They should be made widely available and scaled up rapidly supported by adequate funding with robust monitoring of the uptake to advance global TB elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.